Abstract

Background: The need to develop premotor PD biomarkers is increasingly apparent as early detection of Parkinson's disease (PD) in the premotor stage, which includes some non-motor symptoms, will help patients benefit from potential neuroprotective treatments.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call